Rifapentine Tablet, Film Coated
NDC Package 33342-599-54

11-digit billing NDC: 33342059954 · Billing unit: EA · 24 EA per package

Package Information

Rifapentine tablets are indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. This formulation utilizes a tablet, film coated delivery system. Marketed by Macleods Pharmaceuticals Limited, this product is identified by NDC 33342-599 and is authorized under FDA application ANDA217042.

Identification & Billing

NDC Package Code
33342-599-54
Package Description
3 BLISTER PACK in 1 CARTON / 8 TABLET, FILM COATED in 1 BLISTER PACK (33342-599-20)
Product Code
11-Digit Billing Format
33342059954
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
24 EA
RxNorm Crosswalk
RxCUI: 242671 - rifapentine 150 MG Oral Tablet

Clinical Specifications

Proprietary Name
Rifapentine
Non-Proprietary Name
Rifapentine
Substance Name
Rifapentine
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Rifapentine tablets are indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. Rifapentine tablets must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible [see Dosage and Administration (2.1) and Clinical Studies (14.1)].Limitations of UseDo not use rifapentine tabletsmonotherapy in either the initial or the continuation phases of active antituberculous treatment.Rifapentine tablets should not be used once weekly in the continuation phase regimen in combination with isoniazid (INH) in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (RIF)-resistant organisms [see Warnings and Precautions (5.4) and Clinical Studies (14.1)].Rifapentine tablets have not been studied as part of the initial phase treatment regimen in HIV-infected patients with active pulmonary tuberculosis.

Regulatory & Marketing

Labeler Name
Macleods Pharmaceuticals Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA217042
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-23-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 33342-599-54 identifies a specific commercial package of 3 blister pack in 1 carton / 8 tablet, film coated in 1 blister pack (33342-599-20) of Rifapentine, a human prescription drug labeled by Macleods Pharmaceuticals Limited. This product is billed for "EA" each discreet unit and contains an estimated amount of 24 billable units per package. This tablet, film coated is formulated for oral use and contains rifapentine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Macleods Pharmaceuticals Limited on June 23, 2026. The current certification is valid through December 31, 2027.

How is this Macleods Pharmaceuticals Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 33342059954. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 24 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
33342-599-54
11-Digit CMS (5-4-2)
33342-0599-54

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.